Financial Performance - Sprinklr's Q3 FY26 total revenue showed a year-over-year growth of 9%[8] - The company's total remaining performance obligations (RPO) reached $858 million[8] - Subscription revenue margin was 77% for Q3 FY26[8] - Sprinklr's Q3 FY26 free cash flow was $16 million[8] - The net dollar expansion rate was 102%[8] - The company repurchased $150 million of Class A shares during Q2 and Q3 FY26[41] Customer Base - Sprinklr has 145 customers with over $1 million in revenue[8] Guidance - Sprinklr projects Q4 FY26 subscription revenue to be between $191 million and $192 million, a 5% year-over-year increase at the midpoint[43] - The company anticipates full-year fiscal 2026 total revenue to be between $853 million and $854 million, a 7% year-over-year increase at the midpoint[43]

Transaction Overview - Baldwin Group 将与 CAC Group 合并[1,12] - 总交易对价为 10.26 亿美元（扣除预计递延所得税资产（“DTA”）后为 9.12 亿美元）[12] - 预计到 2028 年底，年度运行协同效应约为 6000 万美元[12] - 预计此次收购将使 2025 年的每股收益增加 20% 以上[12] CAC Group Overview - CAC Group 在 Business Insurance 2025 年美国 100 强经纪商榜单中排名第 35 位[15] - CAC Group 2026 年预计收入为 3.45 亿美元[16] - CAC Group 截至 2025 年 6 月 30 日的 LTM 保费为 22 亿美元[16] - CAC Group 2020 年至 2025 年 6 月 30 日的 LTM 有机收入复合年增长率为 29%[16] - CAC Group 2026 年预计调整后 EBITDA 为 9000 万美元（包括当年协同效应 1000 万美元）[16,17] - CAC Group 顾问的平均年龄为 46 岁[16] Combined Business - Baldwin + CAC 合并后的 2026 年预计总收入为 20.05 亿美元至 20.45 亿美元[21] - Baldwin + CAC 合并后的 2026 年预计调整后 EBITDA 为 4.7 亿美元至 4.9 亿美元[21]

CNM-Au8 & ALS Biomarkers - Clene announced statistically significant ALS biomarker results supporting an accelerated approval pathway for CNM-Au8® [1] - High NfL and GFAP levels are associated with mortality risk in ALS [21] - Substantiation of NfL biomarker effect may support acceptance of survival analyses [7, 28] - FDA guidance suggests that substantiation of NfL effects may allow 24-week data from the HEALEY platform trial and post-hoc analyses on long-term survival to provide evidence of clinical benefit [9, 10] - In the HEALEY ALS platform trial, CNM-Au8 demonstrated consistent effects on NfL and GFAP biomarkers [67] - In HEALEY trial, Plasma NfL W24 LS Mean GMR was 0.905 (95% CI: 0.822 – 0.996, p = 0.0403) and W24 AUC GMR was 0.901 (95% CI: 0.845 – 0.959, p = 0.0013) [69] - In HEALEY trial, Plasma GFAP W24 LS Mean GMR was 0.891 (95% CI: 0.798 – 0.995, p = 0.0401) and W24 AUC GMR was 0.913 (95% CI: 0.841 – 0.990, p = 0.0278) [72, 73] - In NIH-EAP trial, NfL and GFAP AUC decline is also consistent [75] Survival Analysis - NfL change significantly impacts ALS survival, with a joint-model hazard ratio of 1.40 (95% CI: 1.31 – 1.51) [108, 110] - Long-term survival evidence from the HEALEY ALS Platform Trial shows a 73% risk reduction at Month 12 in the Full Analysis Set and a 77% risk reduction in the Comparable Risk Set [113, 130, 133] - Improved long-term survival in ex-placebo to CNM-Au8 group, with a 51% risk reduction at 12-months post-CNM-Au8 treatment initiation [139, 140]

Financial Performance - Royal Bank of Canada (RBC) reported record results, driven by a 29% year-over-year increase in reported net income available to common shareholders[8, 16] - Adjusted net income increased by 25% year-over-year[8, 16] - Pre-Provision, Pre-Tax Earnings (PPPT) grew by 29% year-over-year[8, 16] - Revenue increased by 14% year-over-year to $17209 million[16] - All-bank operating leverage was 103%[8] - The all-bank efficiency ratio was 545%[8] Segment Performance - Personal Banking net income increased by 20% year-over-year[8, 16] - Commercial Banking net income increased by 5% year-over-year[8, 16] - Wealth Management net income increased by 33% year-over-year[8, 16] - Capital Markets net income increased by 45% year-over-year[8, 16] Capital and Dividends - The CET1 ratio was 135%, up 30 bps quarter-over-quarter[8, 20] - RBC repurchased 48 million shares for $987 million[8, 21] - The dividend increased by $010 or 6% quarter-over-quarter[8]

LOTIS-7 Clinical Trial Results and Strategy - The LOTIS-7 trial (ZYNLONTA + glofitamab) showed an overall response rate (ORR) of 89.8% (44/49 patients) in 2L+ LBCL patients[37] - The complete response (CR) rate in the LOTIS-7 trial was 77.6% (38/49 patients)[41] - In the LOTIS-7 trial, 6 out of 8 patients previously treated with CAR-T achieved a CR[41] - Grade 3 or higher treatment emergent adverse events (TEAEs) occurred in >5% of patients, including neutropenia (32.7%), GGT increased (16.3%), and anemia (10.2%)[40] - Grade 5 AEs occurred in 4.1% (2/49) of patients in the LOTIS-7 trial[40] - Cytokine release syndrome (CRS) of any grade was observed in 36.7% (18/49) of patients in the LOTIS-7 trial[47] Market Opportunity and Revenue Potential - ZYNLONTA has a U S peak revenue potential of $600 million to $1 billion in DLBCL and indolent lymphomas[56] - The company believes LOTIS-7 has the potential to be the leading bispecific combination regimen for patients with access to complex therapies[17] - The company believes LOTIS-5 has the potential to be the leading regimen for patients who will not receive complex therapies[17] Upcoming Milestones - The company expects full enrollment of 100 patients at selected dose for LOTIS-7 in 1H2026[59] - The company expects to share topline results for LOTIS-5[59]

Glencore's Strategic Priorities - Glencore aims to be among the world's largest copper producers, with approximately 1.4Mt of incremental long-life annual copper production progressing through planning and approval phases[20, 291] - The company focuses on long-term value creation for shareholders, with $25.3 billion in announced shareholder returns since 2021[23, 294] - Glencore is optimizing its operating structures to promote accountability and delivery[21, 292] Copper Production and Growth - Glencore targets approximately 1.6Mt of copper production by 2035[51] - The company's base copper portfolio aims to return to 1Mt by 2028[47] - The copper project pipeline includes projects with a total indicative capex of approximately $23.4 billion and an average LOM CuEq production of 1410ktpa[52] Financial Performance and Returns - Glencore has announced $25.3 billion in shareholder returns from 2021 to 2025, including base cash distributions, special cash distributions, and buybacks[241] - Approximately 1.6 billion shares have been repurchased, representing approximately 14% of current shares eligible for distributions[41, 243] - The company's copper business can self-fund its full indicative growth pipeline[234] Operational Efficiency and Portfolio Optimization - Glencore has sold or shut down approximately 35 assets since 2021[39] - The company has identified approximately $1 billion of recurring cost-saving opportunities across more than 300 initiatives, expected to be fully delivered by the end of 2026, with over 50% already locked in for 2025[41] - Glencore has streamlined its industrial operating structure, eliminating approximately 1000 roles[67]

Financial Performance Highlights - Macy's Inc's comparable owned-plus-licensed-plus-marketplace (O+L+M) sales increased by 3.2% compared to 3Q24[8, 44] - Adjusted diluted earnings per share (EPS) was $0.09[9, 10] - Net sales were $4.7 billion, a decrease of 0.6% compared to 3Q24, but increased by 2.9% excluding the impact of store closures[40] - Comparable owned sales increased by 2.5% compared to 3Q24[42] - Go-Forward business comparable O+L+M sales increased by 3.4% compared to 3Q24[46] Brand Performance - Macy's nameplate comparable O+L+M sales increased by 2.0% compared to 3Q24[14, 49] - Macy's Go-Forward business comparable O+L+M sales increased by 2.3% compared to 3Q24[14, 49] - Bloomingdale's comparable O+L+M sales increased by 9.0% compared to 3Q24[17, 49] - Bluemercury comparable owned sales increased by 1.1% compared to 3Q24[24, 49] Operational Improvements - Inventory increased by 0.7% compared to 3Q24[29, 50] - Order-to-ship days improved by 11.3%[29, 30] Guidance - The company expects FY25 comparable O+L+M sales to be approximately flat to +0.5% vs FY24 and adjusted diluted EPS to be $2.00 to $2.20[62]

RAPIDe-3 Study Design and Demographics - The RAPIDe-3 study was a double-blind crossover trial evaluating deucrictibant IR 20 mg versus placebo for HAE attacks[17] - The efficacy analyses were based on 88 paired attacks[19] - The study enrolled 134 participants, including 10 adolescents (7.5%) and 124 adults (92.5%)[20] - The median age of participants was 38 years, and 56.7% were female[23] Efficacy Endpoints - Deucrictibant significantly reduced the time to onset of symptom relief to 1.28 hours compared to placebo (p < 0.0001)[35] - Deucrictibant significantly reduced the time to End of Progression (EoP) to 17.47 minutes compared to placebo (p < 0.0001)[38] - Deucrictibant significantly reduced the time to substantial symptom relief by PGI-C to 2.85 hours compared to placebo (p < 0.0001)[42] - Deucrictibant significantly reduced the time to substantial symptom relief by PGI-S to 2.41 hours compared to placebo (p < 0.0001)[47] - Deucrictibant significantly reduced the time to complete symptom resolution to 11.95 hours compared to placebo (p < 0.0001)[51] Treatment and Safety - 83% of attacks were treated with a single capsule of deucrictibant[54] - 93.2% of attacks were treated without rescue medication with deucrictibant versus 63.6% with placebo[54]

Financial Performance - Diluted EPS from continuing operations was $1.20, and adjusted diluted EPS from continuing operations was $1.21[8] - Dollar Tree segment gross margin expanded by 40 bps to 35.8%[9] - Adjusted operating margin contracted 30 bps to 7.3%[9] Sales and Comparable Store Sales - Dollar Tree's comparable store sales increased by 4.2%, driven by a 4.5% increase in average ticket and a 0.3% decrease in traffic[9] - Consumables comparable sales grew by 3.5%, while discretionary comparable sales grew by 4.8%[9] - Discretionary mix increased by 40 bps to 50.5%[9] Real Estate and Store Conversions - The company opened 106 new Dollar Tree stores, ending the quarter with 9,269 open stores[9] - 1,744 multi-price 3.0 format store conversions were completed year-to-date, remaining on track to reach the full-year target of 2,000[9] - 55 Family Dollar combo store conversions to full Dollar Tree stores were completed[9] Balance Sheet and Cash Flow - Inventory decreased by 5% year-over-year, a reduction of $143 million, while sales increased by 9.4%[9] - Year-to-date free cash flow from continuing operations was $88 million, and cash and cash equivalents at quarter-end totaled $595 million[9] - The company repurchased 4.1 million shares in Q3 for $399 million including excise tax, and an additional 1.7 million shares were purchased subsequent to quarter-end for $176 million[9] - Year-to-date, 16.7 million shares were repurchased for $1.5 billion at an average price of $90 per share, representing 8% of shares outstanding at the beginning of the year[9] Updated Outlook for Fiscal Year 2025 - Dollar Tree sales are projected to be between $19.35 billion and $19.45 billion[33] - Comparable sales for Dollar Tree are expected to increase by 5.0% to 5.5%[33] - Adjusted diluted earnings per share are projected to be between $5.60 and $5.80[33]

HOPE-3 Trial Overview - The HOPE-3 Phase 3 trial met both the primary endpoint (PUL v20) and the key secondary cardiac endpoint (LVEF), achieving statistical significance with p=003 and p=004 respectively[27] - Statistical significance was achieved in all type 1 error controlled secondary endpoints[27] - The trial involved 106 patients randomized 1:1 to Deramiocel or placebo[13, 14] - The study population consisted of late-ambulatory patients with DMD and 10MWR > 10 seconds[15] Safety Profile - In the Placebo group, 827% (43/52) experienced any Treatment Emergent Adverse Events (TEAEs), while in the Deramiocel group, 943% (50/53) experienced any TEAEs[18] - TEAEs related to the Investigational Product (IP) or administration procedure were reported in 365% (19/52) of the placebo group and 830% (44/53) of the Deramiocel group[18] - Serious TEAEs occurred in 96% (5/52) of the placebo group and 19% (1/53) of the Deramiocel group[18] Deramiocel Potential - Deramiocel is a potential first-in-class therapy designed to treat DMD skeletal and cardiomyopathy[27] - The company plans to submit a response to the Complete Response Letter incorporating HOPE-3 data, following prior alignment with the FDA[27]